---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-027642"
form_type: "8-K"
ticker: "CRNX"
cik: "0001658247"
company_name: "Crinetics Pharmaceuticals, Inc."
filed_at: "2026-07-06T21:17:19+00:00"
generated_at: "2026-07-06T21:18:05.814008+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Vertex to acquire Crinetics for $85/share, ~$10B equity value, adding PALSONIFY and atumelnant

## Summary
- Vertex to acquire Crinetics for $85.00 per share in cash, total equity value ~$10.0B (~$8.8B net of cash).
- Crinetics' PALSONIFY (once-daily oral for acromegaly) launched in 2025; atumelnant (ACTH receptor antagonist) in Phase 3 for CAH.
- Transaction unanimously approved by both boards; expected to close in Q3 2026, subject to stockholder and regulatory approvals.
- Vertex plans to finance with cash on hand and $4.5B bridge loan from Bank of America and Morgan Stanley.
- Termination fee of ~$350M payable by Crinetics under certain circumstances.

## SEC filing metadata
- accession: 0001140361-26-027642
- form_type: 8-K
- ticker: CRNX
- cik: 0001658247
- company_name: Crinetics Pharmaceuticals, Inc.
- filed_at: 2026-07-06T21:17:19+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658247/000114036126027642/0001140361-26-027642-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658247/000114036126027642/ef20077399_form8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-027642
- JSON: https://secwatch.observer/filing/0001140361-26-027642.json
- Plain text: https://secwatch.observer/filing/0001140361-26-027642.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.